AdAlta (ASX:1AD) Buildings And Improvements : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Buildings And Improvements?

AdAlta Buildings And Improvements Historical Data

The historical data trend for AdAlta's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Buildings And Improvements Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Buildings And Improvements

Get a 7-Day Free Trial

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Buildings And Improvements	Get a 7-Day Free Trial											-	-	-	-	-

AdAlta Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

AdAlta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Science Drive, La Trobe Institute for Molecular Science, Room 204, LIMS2, La Trobe University, Bundoora, VIC, AUS, 3086

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines